<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889211</url>
  </required_header>
  <id_info>
    <org_study_id>16060315</org_study_id>
    <nct_id>NCT02889211</nct_id>
  </id_info>
  <brief_title>Brain Function in Depression and Insulin Resistance</brief_title>
  <official_title>Brain Function in Depression and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help researchers learn about how the brain responds to&#xD;
      rewards. This study is interested in seeing how these responses differ between people who are&#xD;
      more and less responsive to insulin in their body, and people with and without depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator Left University&#xD;
  </why_stopped>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI BOLD Response in Striatal Regions</measure>
    <time_frame>During Gambling Task in fMRI Scanner</time_frame>
    <description>The investigators will monitor the blood oxygen level dependent response using fMRI and compare activation during &quot;win&quot; trials vs. &quot;loss&quot; trials</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Depression</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Metabolically Healthy - Non-depressed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Overweight individuals without metabolic syndrome and free of psychiatric illness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metabolically Healthy - Depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overweight individuals without metabolic syndrome and with active major depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Resistant - Depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overweight individuals with metabolic syndrome and active major depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Resistant - Non-depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overweight individuals with metabolic syndrome and free of psychiatric illness</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Gambling Task</intervention_name>
    <arm_group_label>Insulin Resistant - Depressed</arm_group_label>
    <arm_group_label>Insulin Resistant - Non-depressed</arm_group_label>
    <arm_group_label>Metabolically Healthy - Depressed</arm_group_label>
    <arm_group_label>Metabolically Healthy - Non-depressed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Body Mass Index 24-34.9&#xD;
&#xD;
        HEALTHY CONTROLS HOMA-IR (fasting (glucose x insulin)/405) &lt; 1.8&#xD;
&#xD;
        Not more than one of the following:&#xD;
&#xD;
          -  Waist circumference &gt; 40 inches (men) or &gt; 35 inches (women)&#xD;
&#xD;
          -  Triglycerides &gt; 150 mg/dL&#xD;
&#xD;
          -  HDL &lt; 40 mg/dL (men) or &lt; 50 mg/dL (women)&#xD;
&#xD;
          -  Blood pressure &gt; 135/85&#xD;
&#xD;
          -  Fasting glucose &gt; 100 mg/dL&#xD;
&#xD;
        INSULIN RESISTANT HOMA-IR &gt; 2.0&#xD;
&#xD;
        And at least three of the following:&#xD;
&#xD;
          -  Waist circumference &gt; 40 inches (men) or &gt;35 inches (women)&#xD;
&#xD;
          -  Triglycerides &gt; 150 mg/dL&#xD;
&#xD;
          -  HDL &lt; 40 mg/dL (men) or &lt;50 mg/dL (women)&#xD;
&#xD;
          -  Blood pressure &gt; 135/85&#xD;
&#xD;
          -  Fasting glucose &gt; 100 mg/dL&#xD;
&#xD;
        MAJOR DEPRESSION, METABOLICALLY HEALTHY Meets criteria for MDD during SCID-5 evaluation&#xD;
        HOMA-IR &lt; 1.8&#xD;
&#xD;
        Not more than one of the following:&#xD;
&#xD;
          -  Waist circumference &gt; 40 inches (men) or &gt;35 inches (women)&#xD;
&#xD;
          -  Triglycerides &gt; 150 mg/dL&#xD;
&#xD;
          -  HDL &lt; 40 mg/dL (men) or &lt;50 mg/dL (women)&#xD;
&#xD;
          -  Blood pressure &gt; 135/85&#xD;
&#xD;
          -  Fasting glucose &gt; 100 mg/dL&#xD;
&#xD;
        MAJOR DEPRESSION, INSULIN RESISTANT Meets criteria for MDD during SCID-5 evaluation HOMA-IR&#xD;
        &gt; 2.0&#xD;
&#xD;
        And at least three of the following:&#xD;
&#xD;
          -  Waist circumference &gt; 40 inches (men) or &gt;35 inches (women)&#xD;
&#xD;
          -  Triglycerides &gt; 150 mg/dL&#xD;
&#xD;
          -  HDL &lt; 40 mg/dL (men) or &lt;50 mg/dL (women)&#xD;
&#xD;
          -  Blood pressure &gt; 135/85&#xD;
&#xD;
          -  Fasting glucose &gt; 100 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - History of mania or psychosis&#xD;
&#xD;
          -  Current suicidal ideation&#xD;
&#xD;
          -  Alcohol or substance abuse including cannabis use (current or in the last three&#xD;
             months)&#xD;
&#xD;
          -  Early onset dementia of any etiology&#xD;
&#xD;
          -  Medical conditions with known significant effects on mood (e.g. Stroke or current&#xD;
             hypothyroid state)&#xD;
&#xD;
          -  Unstable medical illnesses (e.g. Delirium, uncontrolled DM, uncontrolled&#xD;
             cardiovascular illness)&#xD;
&#xD;
          -  Use of high doses of benzodiazepines (&gt; 2mg lorazepam/day equivalent)&#xD;
&#xD;
          -  Given the high comorbidity (80%) between MDD and anxiety disorders, participants with&#xD;
             comorbid anxiety disorders will be included in the study as long as the clinical&#xD;
             presentation suggests that depression precedes the onset of anxiety&#xD;
&#xD;
          -  Current or lifetime history of cancer, a chronic kidney or liver condition, type I or&#xD;
             II diabetes&#xD;
&#xD;
          -  Current or lifetime use of glucocorticoid medications for &gt;1 month&#xD;
&#xD;
          -  Previous cerebrovascular accident or trauma involving loss of consciousness&#xD;
&#xD;
          -  Previous neurosurgery or history of a neurological condition&#xD;
&#xD;
          -  Pregnancy (females)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Ferrous metallic implants or any surgically placed medical device not cleared for&#xD;
             safety at 3Tesla MRI strength&#xD;
&#xD;
          -  Positive Hepatitis C serology or other known viral infections that may induce insulin&#xD;
             resistance&#xD;
&#xD;
          -  Peripheral vascular disease&#xD;
&#xD;
          -  Liver, kidney, or active blood disease&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Fasting glucose &gt; 126 mg/dL&#xD;
&#xD;
          -  Currently taking any medications that can alter glucose homeostasis (steroids,&#xD;
             glucocorticoids, nicotinic acid)&#xD;
&#xD;
          -  Currently taking thiazolidinediones or insulin&#xD;
&#xD;
          -  Females currently on hormone replacement therapy (HRT) less than 6 months&#xD;
&#xD;
          -  Being left handed&#xD;
&#xD;
          -  Use of antidepressant medication within the past two weeks (six weeks fluoxetine)&#xD;
&#xD;
          -  Suicide risk&#xD;
&#xD;
          -  Current use of stimulants, antipsychotic medications, mood stabilizers, cognitive&#xD;
             enhancers, statins, glucocorticoids, steroids, nicotinic acid, thiazolidinediones,&#xD;
             insulin, metformin, any diabetes medications (e.g. gliptins), HIV medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic at University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>December 2, 2017</last_update_submitted>
  <last_update_submitted_qc>December 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>John Patrick Ryan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

